Entest Biomedical Inc (OTC:ENTB) announced that the Company’s unique treatments for Chronic Obstructive Pulmonary Disease also known as COPD, which is currently under development, can lead to substantial revenue opportunities in the near future. Entest Biomedical’s CEO and Chairman, David Koos stated that the current treatment for COPD is aimed at improving the quality of life of the patient and not curing the illness. Hence, Entest is working hard to reverse the damage from COPD.
Entest Biomedical Inc is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. Currently, the Company is into the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), testing procedures for diabetes, immuno-therapies for cancer, stem cell research applications for other illnesses and diabetes. The Company also is involved with medical device development (including stem cell extraction instrumentation). Entest is also seeking grant funding in excess of $3 million to support its research and is applying for government development contracts. And over the next five years, Entest Biomedical has decided that they will spend US$170 billion for the treatment of COPD in the United States.
COPD is the 4th leading cause of death in the United States and is projected that in next ten years it will be the 3rd leading cause of death in the United States. It is also estimated that more than US$800 billion will be spent on the medical related costs to combat chronic obstructive pulmonary disease. David Koos also stated that they might soon come up with a photoceutical device to direct stem cells to targeted damaged lung tissue which may actually reverse the impact and effects of COPD
Entest BioMedical, Inc.
8885 Rehco Road
San Diego, California 92122
Middle East contact
No office in Middle East